Eli Lilly and Company (LLY)vsSenseonics Holdings, Inc. Common Stock (SENS)
LLY
Eli Lilly and Company
$1,131.42
-0.32%
HEALTHCARE · Cap: $948.95B
SENS
Senseonics Holdings, Inc. Common Stock
$6.67
-4.85%
HEALTHCARE · Cap: $357.07M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 204821% more annual revenue ($72.25B vs $35.26M). LLY leads profitability with a 35.0% profit margin vs -196.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SENS
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 71.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SENS
The strongest argument for SENS centers on Revenue Growth. Revenue growth of 71.8% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SENS
The primary concerns for SENS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while SENS is a hypergrowth play — different risk/reward profiles.
SENS carries more volatility with a beta of 1.06 — expect wider price swings.
SENS is growing revenue faster at 71.8% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 24/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Senseonics Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Senseonics Holdings, Inc., a medical technology company, develops and markets continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company is headquartered in Germantown, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?